NASDAQ
PHAS

PhaseBio Pharmaceuticals Inc

Biotechnology & Medical Research
Healthcare

Prices are adjusted according to historical splits.

PhaseBio Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$0.0324
Today's High:
$0.04
Open Price:
$0.04
52W Low:
$0.0111
52W High:
$1.19
Prev. Close:
$0.038
Volume:
285749

Company Statistics

Market Cap.:
$3.50 million
Book Value:
-2.355
Revenue TTM:
$818000
Operating Margin TTM:
-12738.63%
Gross Profit TTM:
$-91276000
Profit Margin:
0%
Return on Assets TTM:
-106.07%
Return on Equity TTM:
-3091.02%

Company Profile

PhaseBio Pharmaceuticals Inc had its IPO on 2018-10-18 under the ticker symbol PHAS.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. PhaseBio Pharmaceuticals Inc has a staff strength of 60 employees.

Stock update

Shares of PhaseBio Pharmaceuticals Inc opened at $0.04 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.03 - $0.04, and closed at $0.04.

This is a +5.26% increase from the previous day's closing price.

A total volume of 285,749 shares were traded at the close of the day’s session.

In the last one week, shares of PhaseBio Pharmaceuticals Inc have increased by +75.44%.

PhaseBio Pharmaceuticals Inc's Key Ratios

PhaseBio Pharmaceuticals Inc has a market cap of $3.50 million, indicating a price to book ratio of 26.18 and a price to sales ratio of 4.2727.

In the last 12-months PhaseBio Pharmaceuticals Inc’s revenue was $818000 with a gross profit of $-91276000 and an EBITDA of $-102262000. The EBITDA ratio measures PhaseBio Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, PhaseBio Pharmaceuticals Inc’s operating margin was -12738.63% while its return on assets stood at -106.07% with a return of equity of -3091.02%.

In Q2, PhaseBio Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98%.

PhaseBio Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PhaseBio Pharmaceuticals Inc’s profitability.

PhaseBio Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.1964 and a EV to EBITDA ratio of -0.0016. Its price to sales ratio in the trailing 12-months stood at 4.2727.

PhaseBio Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$22.17 million
Total Liabilities
$24.68 million
Operating Cash Flow
$-58000.00
Capital Expenditure
$58000
Dividend Payout Ratio
0%

PhaseBio Pharmaceuticals Inc ended 2024 with $22.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $22.17 million while shareholder equity stood at $-117398000.00.

PhaseBio Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $24.68 million in other current liabilities, 50000.00 in common stock, $-419600000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.80 million and cash and short-term investments were $7.80 million. The company’s total short-term debt was $4,503,000 while long-term debt stood at $0.

PhaseBio Pharmaceuticals Inc’s total current assets stands at $11.56 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $6.32 million and inventory worth $0.

In 2024, PhaseBio Pharmaceuticals Inc's operating cash flow was $-58000.00 while its capital expenditure stood at $58000.

Comparatively, PhaseBio Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.04
52-Week High
$1.19
52-Week Low
$0.0111
Analyst Target Price
$16

PhaseBio Pharmaceuticals Inc stock is currently trading at $0.04 per share. It touched a 52-week high of $1.19 and a 52-week low of $1.19. Analysts tracking the stock have a 12-month average target price of $16.

Its 50-day moving average was $0.06 and 200-day moving average was $0.71 The short ratio stood at 1.89 indicating a short percent outstanding of 0%.

Around 672.1% of the company’s stock are held by insiders while 5520.5% are held by institutions.

Frequently Asked Questions About PhaseBio Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of PhaseBio Pharmaceuticals Inc is PHAS

The IPO of PhaseBio Pharmaceuticals Inc took place on 2018-10-18

Similar Industry Stocks (Biotechnology & Medical Research)

Last Price
Chg
Chg%
$15.74
0.68
+4.52%
$83.91
-3.26
-3.74%
$0.04
-0
-6.8%
$23.59
-0.21
-0.88%
$0.14
0
0%
$1686.65
-12.3
-0.72%
Seagen Inc (SGEN)
$207.35
-0.78
-0.37%
$22.15
-0.01
-0.05%
$2.39
0.03
+1.27%
$1063.5
-63.6
-5.64%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Address

1 Great Valley Parkway, Malvern, PA, United States, 19355